| 发明名称 | Use of glycerophosphoinositols for the treatment of septic shock | ||
| 摘要 | The present invention refers to glycerophosphoinositols (GPIs) and derivatives thereof for use in the treatment of pathologies related to a Lipopolysaccharide (LPS)-activated tissue-factor (TF) activity, as pathologies induced by high bacteremia, i.e. septic shock. | ||
| 申请公布号 | US9351983(B2) | 申请公布日期 | 2016.05.31 |
| 申请号 | US201314433406 | 申请日期 | 2013.10.04 |
| 申请人 | CONSIGLIO NAZIONALE DELLE RICERCHE | 发明人 | Corda Daniela;Zizza Pasquale;Luini Alberto;Mariggio' Stefania |
| 分类号 | A61K31/66;A61K31/683 | 主分类号 | A61K31/66 |
| 代理机构 | Lucas & Mercanti, LLP. | 代理人 | Lucas & Mercanti, LLP. |
| 主权项 | 1. A method for treating or reducing the severity of a symptom of sepsis, severe sepsis or septic shock related to a Lipopolysaccharide (LPS)-activated pro-coagulant tissue-factor (TF) activity, comprising administering a therapeutically effective amount of a Glycerophosphoinostitol (GPI) or derivative thereof to inhibit pro-coagulant TF activity in a mammal in need thereof, wherein said sepsis, severe sepsis or septic shock is not mediated by an activation or over-stimulation of cPLA2, PLA2IVα or any other isoform. | ||
| 地址 | Rome (RM) IT | ||